Broad vs Narrow Meta Ad Audiences for Healthcare — The Per-Specialty Verdict
Why "broad always" and "narrow always" are both wrong
The fixed-philosophy camps each have an argument:
- Broad camp: Meta's algorithm is smart enough to find the right audience within a broad pool. Trust the algorithm.
- Narrow camp: Healthcare patients are specific. Targeting must reflect that specificity. Don't waste impressions on irrelevant audiences.
Both are right sometimes and wrong other times. The right framing isn't "what's my philosophy" — it's "what's the verdict for my account this week."
Per-specialty audience baselines
Across the ICG portfolio, the typical optimal audience size by specialty:
- IVF — 2-10M narrow (specific intent + age-banded). Above 15M, CPL rises sharply because of low-intent dilution.
- Dental implants — 2-8M narrow. Patient persona is fairly specific (age 35-65, income tier-1).
- Orthopaedic joint replacement — 5-15M narrow. Age 50+ targeting with specific income + location bands.
- Aesthetic + cosmetic derm — 10-25M broader. Demand is wider; Meta's algorithm efficiency higher with broader pool.
- Hair transplant — 8-18M moderate. Mix of broad demand + specific intent signals.
- Cardiac surgery — 5-15M narrow with specific city + age slicing. Very high-trust consideration.
- Paediatric — 5-15M moderate. Mother-persona targeting + geographic specificity.
- Mental health / psychiatry — 10-25M broader. Stigma-aware targeting; broader serves anonymity-preferring patients.
Why the answer shifts week-to-week
Three factors shift the broad vs narrow optimal:
1. Audience saturation
Run a 5M narrow audience for 8-12 weeks; you'll exhaust the optimal pool. CPL rises. Same week, expanding to 15M broader audience can reduce CPL because the algorithm finds adjacent intent signals in the wider pool.
2. Competitive intensity
When a competitor enters your specialty + city with aggressive Meta spend, your narrow audience CPM rises faster than the broader audience CPM (because competitors target the same narrow pool). Shifting broader during a competitor escalation can preserve CPL.
3. Seasonality
Aesthetic specialties around festival + wedding season: broader audience works because everyone is in-market. Off-season: narrower works because only intent-driven patients are searching.
The weekly verdict methodology
Meta Catalyst IQ's Audience Size verdict each Monday checks 5 inputs:
- CPL by audience size bucket (≤2M, 2-10M, 10-20M, 20M+) over last 7 days
- Hold Rate by audience size bucket
- Result Rate by audience size bucket
- CPM trend by bucket (rising → saturation signal)
- Frequency by bucket (high frequency → saturation imminent)
The output: which audience size delivered best CPL × engagement quality this week, and the reallocation recommendation for next week (typically 10-25% budget shift).
3 common mistakes in audience strategy
- Building 50+ ad sets for granularity. Meta's algorithm needs 50-100 conversions per ad set to optimise. With 50 ad sets, none get to threshold. Better: 5-12 ad sets with broader audiences, let the algorithm optimise within.
- Refusing to test broader. The "we know our patient" instinct keeps brands locked into narrow audiences past saturation. Test broader monthly even if you don't expect it to win.
- Not segmenting NRI vs domestic. NRI audiences have completely different economics + targeting needs. Should never be in the same ad set as domestic.
Get your account's audience verdict.
ICG runs a 48-hour audit on your Meta account that surfaces current audience size performance, saturation signals, and the recommended reallocation. Read-only OAuth access.
Book a free audit → WhatsApp ICGRelated reading
- Meta Catalyst IQ product page
- 12-point Hygiene Factors
- Creative Scoring Matrix
- CPL benchmarks by specialty
Sources & methodology +
Primary data — ICG's live client portfolio (150+ healthcare brands, 12+ specialties, since 2018): CPQL, EMQ, lead-to-consult conversion, cohort MRR:CAC. All numbers are portfolio aggregates unless a specific client is named.
Platform data — Google Search Console (impressions, CTR, position), Google Analytics 4 (session behaviour, conversion paths), Meta Ads Manager (EMQ, CTWA, CAPI event quality), Google Ads (search terms, quality score, intent-tier classification), Angryturtle GBP portfolio (143 listings under management).
Regulatory sources — NMC Ethics Code 2026, DPDP Act 2023, ART (Regulation) Act 2021, NABH 6th Edition, ASCI Healthcare Guidelines — cited when the article references compliance obligations. Regulatory interpretations are current as of the article's last-updated date.
Third-party research — When cited, sources are named inline (Practo, PwC India Healthcare, McKinsey Life Sciences, etc.) with the publication year. If a stat has no citation, it comes from ICG's own portfolio.
Methodology transparency — See /about/methodology for the diagnostic framework used to produce these insights, and /editorial-standards for the fact-check + review workflow every published article goes through.
Got it, .
A founder will reach out within one business day. In the meantime — WhatsApp Rohit directly for the fastest reply.
💬 Message Rohit on WhatsApp
Hi, I'm Rohit. Co-Founder, ICG.
Right process, right systems, right ecosystem. If you're systems-driven and data-driven about your healthcare brand, let's talk. I reply personally.
Message Rohit on WhatsAppOr call: +91 81302 26224